AstraZeneca PLC (AZN)vsRani Therapeutics Holdings Inc (RANI)
AZN
AstraZeneca PLC
$184.74
-1.40%
HEALTHCARE · Cap: $287.11B
RANI
Rani Therapeutics Holdings Inc
$0.94
+5.87%
HEALTHCARE · Cap: $108.42M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 3596899% more annual revenue ($58.74B vs $1.63M). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
RANI
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$184.74
$29.77 discount
Margin of Safety
+62.9%
Fair Value
$3.37
Current Price
$0.94
$2.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 42.1% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : RANI
The strongest argument for RANI centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 42.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a value stock while RANI is a hypergrowth play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.66 — expect wider price swings.
RANI is growing revenue faster at 42.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 31/100), backed by strong 17.4% margins. RANI offers better value entry with a 62.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is a pioneering biotechnology firm that revolutionizes injectable therapeutic delivery through its proprietary RaniPill™ technology, enabling the oral administration of biologics. This innovative platform not only enhances patient adherence but also improves treatment outcomes, effectively addressing critical gaps in the healthcare landscape. With a diverse pipeline targeting various therapeutic areas, Rani Therapeutics is well-positioned to disrupt conventional drug delivery methods while leveraging the increasing demand for non-invasive treatment solutions. Furthermore, the company's strategic collaborations and strong emphasis on research and development highlight its potential for substantial growth and meaningful contributions to the pharmaceutical sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?